Additionally, our data show that vascular ephrinB2 loss combined with RT enhanced systemic CD4+ and CD8+ T cell activation, trended towards decreased Treg immunosuppression, and reduced CD4+ T cell entry into the tumor. This evidence concerns the gene EFNB2 and neoplasm.